Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Poolbeg Pharma Ltd. ( (GB:POLB) ) has issued an update.
Poolbeg Pharma has announced its interim results for the first half of 2025, highlighting a strong cash position and extended financial runway into 2027. The company is advancing its POLB 001 Phase 2a trial, which aims to prevent CRS in cancer immunotherapy patients, with interim data expected in 2026. The trial will be conducted at leading UK cancer centers, and the company has secured a bispecific antibody drug for the trial at no cost. POLB 001 has received Orphan Drug Designation from the FDA, enhancing its commercial appeal. Poolbeg is also progressing with an oral GLP-1 trial for obesity, with topline data anticipated in 2026. These developments position Poolbeg for potential partnerships and value creation for shareholders.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focused on transforming the cancer immunotherapy field. The company aims to expand the administration of cancer immunotherapies from specialized cancer centers to community hospitals by preventing Cytokine Release Syndrome (CRS), a life-threatening side effect. Poolbeg is also developing an oral encapsulated GLP-1 therapy for obesity, targeting large markets and addressing critical unmet medical needs.
Average Trading Volume: 1,407,724
Technical Sentiment Signal: Buy
Current Market Cap: £27.19M
Learn more about POLB stock on TipRanks’ Stock Analysis page.